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Background: Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing 
intraoccular pressure (IOP) based on two double-masked, active-controlled clinical trials. Four 
additional long-term studies ($12 months) were conducted; however, the aggregate safety 
profile of the six studies has not been reported.
Methods: Adverse events (AEs) were pooled from six double-masked, active-controlled, long-
term clinical trials in which subjects received bimatoprost 0.03% once daily (QD) or twice 
daily (BID) as an eyedrop. AE terms were converted to MedDRA (V .11.0) Preferred Terms 
and analyzed.
Results: In total, 1409 patients received more than one dose of bimatoprost 0.03% QD or BID. 
Most AEs were mild in severity and reported by 86.7% (QD) and 94.8% (BID) of subjects 
(#12 months of treatment). AEs reported through month 12 (aggregate incidence of $5%) were 
conjunctival hyperemia, increased eyelash growth, eye pruritus, periocular skin hyperpigmen-
tation, eye irritation, dry eye, and hypertrichosis. AE onset was generally reported within four 
months of treatment. The cumulative incidence of common AEs in the QD treatment group at 
24–48 months was similar to that measured at 12 months of treatment.
Conclusion: Bimatoprost 0.03% has a favorable safety and tolerability profile as character-
ized by six long-term studies. Common AEs were due to the known pharmacological activity 
of bimatoprost and reversible with treatment cessation.
Keywords: intraocular pressure, eyelids, pharmacology, clinical trial, medical treatment
Introduction
Bimatoprost is a prostamide, a synthetic prostaglandin structural analog, approved by 
the US Food and Drug Administration (FDA) in 2001, and is being used worldwide for 
glaucoma treatment.1 Bimatoprost ophthalmic solution 0.03% (Lumigan®, Allergan, 
Inc, Irvine, CA) exposure has been estimated to be approximately 11.25 million 
  patient-years worldwide, with 6.1 million patient-years in the US alone (data on file, 
Allergan, Inc). Bimatoprost reduces intraocular pressure (IOP)   primarily by increasing 
aqueous humor outflow via the uveoscleral outflow pathway; bimatoprost also appears 
to act via the trabecular meshwork.2–5 The safety and efficacy of bimatoprost ophthal-
mic solution 0.03% administered as an eyedrop for glaucoma treatment has been well 
studied and repeatedly demonstrated in trials lasting up to 48 months.6–10
In December 2008, bimatoprost ophthalmic solution 0.03% received FDA approval 
for an additional indication of hypotrichosis of the eyelashes, marketed as Latisse® Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  (bimatoprost 0.03% ophthalmic solution, Allergan, Inc). It is 
the first and only FDA-approved treatment to increase eye-
lash growth, as measured by length,   thickness/fullness, and 
darkness.11 The efficacy and safety of bimatoprost ophthalmic 
solution 0.03% to enhance eyelash prominence was estab-
lished in a phase III, multicenter, randomized, double-masked, 
vehicle-controlled study in which bimatoprost ophthalmic 
solution 0.03% was applied to the upper eyelid margins of 
healthy subjects (n = 278) once daily (QD) for up to four 
months, followed by a one-month treatment-free follow-up 
period.12 The use of bimatoprost in the treatment of eyelash 
hypotrichosis was recently reviewed elsewhere.13
The efficacy of bimatoprost ophthalmic solution 0.03% 
was demonstrated by statistically significant improvements in 
clinician ratings and digital image analysis assessing eyelash 
length, fullness, and darkness as compared with vehicle; 
these improvements were sustained during the one-month 
treatment-free follow-up period.12 Findings were supported 
by statistically significant differences in patient-reported 
outcomes favoring bimatoprost ophthalmic solution 0.03% 
over vehicle, beginning at week 1 and sustained through the 
treatment and posttreatment follow-up periods.12 The inci-
dence of adverse events (AEs) was generally similar between 
treatment groups; conjunctival hyperemia was the only AE 
reported in a significantly greater number of subjects receiv-
ing bimatoprost ophthalmic solution 0.03% (3.6% [n = 5]) 
than vehicle (0%, P = 0.03).12
Because treatment with IOP-lowering medications is 
expected to be lifelong in most patients, establishing the 
long-term safety and efficacy of bimatoprost ophthalmic 
solution 0.03% is important to the medical community and 
regulatory authorities. Long-term safety of bimatoprost 
ophthalmic solution 0.03% for hypotrichosis is important 
because its benefit is cosmetic rather than medical. The 
volume of solution of bimatoprost applied to the upper 
eyelid is approximately 5% of that delivered as an eyedrop 
for glaucoma treatment (Pers comm; Allergan, Inc, 2011). 
Therefore, a long-term safety analysis from studies of 
bimatoprost ophthalmic solution 0.03% QD or twice daily 
(BID) in glaucoma treatment, which provides a 20-fold (QD 
administration) to 40-fold (BID administration) increased 
dosing profile applied to the eye versus bimatoprost oph-
thalmic solution 0.03% when applied to the eyelid skin, may 
be interpolated to support the long-term safety of dermal 
application for hypotrichosis.
The long-term safety of bimatoprost ophthalmic 
solution 0.03% in glaucoma treatment was evaluated in 
six previously published, double-masked, randomized, 
active-controlled multicenter clinical trials.6–9,14–17 Although 
summarized   individually, the aggregate long-term safety 
profile of bimatoprost ophthalmic solution 0.03% as dem-
onstrated in the six clinical studies has not previously been 
reported, and is of interest with respect to its new indication. 
Therefore, a pooled analysis of bimatoprost ophthalmic 
solution 0.03% safety based on results from the studies 
was conducted.
Methods
study population in long-term  
glaucoma studies
This analysis includes pooled individual patient data from six 
glaucoma clinical trials, conducted from 1998 to 2007, and 
selected as a representation of the long-term safety profile 
of bimatoprost ophthalmic solution 0.03%. All studies were 
masked, randomized, controlled, phase III studies contain-
ing at least one treatment group that received bimatoprost 
ophthalmic solution 0.03% (without adjunctive therapy), and 
were at least 12 months in duration. Patients randomized to 
the bimatoprost ophthalmic solution 0.03% treatment arms 
in these studies received one drop QD to both eyes for up to 
48 months or one drop BID to both eyes for up to 24 months. 
Patients in the active comparator groups received either 0.5% 
timolol or exploratory bimatoprost formulations; these patients 
were not included in this analysis and are not described further. 
All studies had prospectively defined efficacy endpoints, and 
all based the safety analysis on a tabulation of AE and serious 
AEs (SAEs). The study population for the pooled analysis 
comprised all patients (n = 1409) who received at least one 
dose of bimatoprost ophthalmic solution 0.03% QD or BID 
as an eyedrop.
summary of individual studies
Studies 1 and 2 were randomized, multicenter, double-masked, 
parallel-group, 12-month phase III studies in which patients 
received bimatoprost ophthalmic solution 0.03% QD or BID, 
or timolol 0.5% BID.7,8,14 Study 3 was a double-masked exten-
sion study involving patients enrolled in study 1 or 2 in which 
patients received bimatoprost ophthalmic solution 0.03% QD 
or timolol 0.5% BID for up to 48 months; patients who had 
been randomized to BID bimatoprost ophthalmic solution 
0.03% continued this treatment through 24 months and were 
switched to QD administration through 48 months.6,9 Stud-
ies 4 and 5 were randomized, multicenter,   double-masked, 
parallel-group studies in which patients received bimatoprost 
ophthalmic solution 0.03% QD, timolol 0.5% BID, or a fixed 
combination of bimatoprost ophthalmic solution 0.03% plus Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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timolol 0.5% QD for three months, followed by a masked 
extension of nine months.15,16 Study 6 was a randomized, 
multicenter, double-masked, parallel-group study in which 
patients received bimatoprost 0.03%, bimatoprost 0.01%, 
or bimatoprost 0.0125% QD for three months followed by a 
masked extension of nine months.17
All studies were conducted in accordance with appli-
cable institutional review board regulations and in compli-
ance with informed consent regulations and Good Clinical 
Practice guidelines.6–9,14–17 Randomization schedules and 
sample size calculations have been previously described 
(Pers comm; Allergan, Inc, 2011).6–9,14–17 Primary and 
secondary endpoints of the six studies were prospectively 
defined (Table 1).
Key inclusion criteria for the studies were similar, 
ie, enrolled patients had primary open-angle glaucoma, 
chronic closed-angle glaucoma with patent iridotomy, pseu-
doexfoliative glaucoma, pigmentary glaucoma, or ocular 
hypertension requiring bilateral treatment, and were either 
treatment-naive (IOP $ 22 mmHg or 24 mmHg at baseline) 
or had inadequate IOP control (IOP $18 mmHg in at least 
one eye) on current therapy. Patients were excluded if they 
had a contraindication to any study medication, experienced 
functionally significant visual field loss during the past 
year, or had filtering surgery within the past six months, or 
any other intraocular surgery within the past three months. 
Women who were pregnant, nursing, or of childbearing 
potential, or were not using reliable birth control were also 
excluded.6–9,14–17 Table 1 summarizes the study designs, 
number of patients randomized to treatment groups, pro-
spectively defined primary efficacy endpoints, and patient 
age information for studies 1–6.
safety analyses
Briefly, the analysis of demographic, baseline characteristics, 
and safety data were performed on the safety population, 
which consists of all subjects who received at least one dose 
of study medication.
For each AE (regardless of causality) and treatment-
related AEs, a frequency distribution (numbers, percentages) 
was tabulated by primary system organ class and preferred 
terms. Analyses were performed for AEs occurring during the 
first 12 months or over the entire study period (48 months) 
by treatment group (bimatoprost QD ophthalmic solution 
0.03% versus bimatoprost BID ophthalmic solution 0.03%). 
  Additionally, for subjects involved in the double-blind and 
open-label extension studies (studies 1, 2, and 3) with 
treatment exposure up to 48 months, safety analyses were 
T
a
b
l
e
 
1
 
s
u
m
m
a
r
y
 
o
f
 
s
t
u
d
i
e
s
 
i
n
c
l
u
d
e
d
 
i
n
 
p
o
o
l
e
d
 
a
n
a
l
y
s
i
s
 
o
f
 
b
i
m
a
t
o
p
r
o
s
t
 
o
p
h
t
h
a
l
m
i
c
 
s
o
l
u
t
i
o
n
 
0
.
0
3
%
 
i
n
 
g
l
a
u
c
o
m
a
 
t
r
e
a
t
m
e
n
t
S
t
u
d
y
 
n
u
m
b
e
r
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
e
n
r
o
l
l
e
d
 
i
n
 
e
a
c
h
 
g
r
o
u
p
S
t
u
d
y
 
d
u
r
a
t
i
o
n
,
 
m
o
n
t
h
s
S
t
u
d
y
 
d
e
s
i
g
n
P
r
i
m
a
r
y
 
e
f
fi
c
a
c
y
 
e
n
d
p
o
i
n
t
M
e
a
n
 
a
g
e
 
(
r
a
n
g
e
)
,
 
y
e
a
r
s
Q
D
 
b
i
m
a
t
o
p
r
o
s
t
 
o
p
h
t
h
a
l
m
i
c
 
s
o
l
u
t
i
o
n
 
0
.
0
3
%
B
I
D
 
b
i
m
a
t
o
p
r
o
s
t
 
o
p
h
t
h
a
l
m
i
c
 
s
o
l
u
t
i
o
n
 
0
.
0
3
%
C
o
m
p
a
r
a
t
o
r
 
g
r
o
u
p
s
1
8
,
1
4
2
4
0
2
4
0
1
2
2
1
2
r
,
 
D
M
,
 
A
C
,
 
P
G
I
O
P
 
a
t
 
8
a
m
,
 
1
0
a
m
,
 
4
p
m
6
0
.
7
 
(
2
2
–
9
0
)
2
7
,
8
2
3
4
2
4
3
1
1
9
1
2
r
,
 
D
M
,
 
A
C
,
 
P
G
I
O
P
 
a
t
 
8
a
m
,
 
1
0
a
m
,
 
4
p
m
6
2
.
4
 
(
2
6
–
9
2
)
3
a
6
,
9
1
6
7
1
3
1
8
1
3
6
r
,
 
D
M
,
 
A
C
,
 
P
G
I
O
P
 
r
e
d
u
c
t
i
o
n
 
f
r
o
m
 
b
a
s
e
l
i
n
e
6
2
.
1
 
(
3
2
–
9
1
)
4
1
5
,
1
6
 
c
o
m
p
a
r
a
t
o
r
s
:
 
t
i
m
o
l
o
l
 
0
.
5
%
,
 
e
x
p
l
o
r
a
t
o
r
y
 
b
i
m
a
t
o
p
r
o
s
t
 
f
o
r
m
u
l
a
t
i
o
n
1
2
9
–
3
9
1
1
2
r
,
 
D
M
,
 
A
C
,
 
P
G
I
O
P
 
a
t
 
0
,
 
2
,
 
8
 
h
o
u
r
s
5
9
.
4
 
(
2
2
–
9
1
)
5
1
5
,
1
6
 
c
o
m
p
a
r
a
t
o
r
s
:
 
t
i
m
o
l
o
l
 
0
.
5
%
,
 
e
x
p
l
o
r
a
t
o
r
y
 
b
i
m
a
t
o
p
r
o
s
t
 
f
o
r
m
u
l
a
t
i
o
n
1
3
6
–
4
0
5
1
2
r
,
 
D
M
,
 
A
C
,
 
P
G
I
O
P
 
a
t
 
0
,
 
2
,
 
8
 
h
o
u
r
s
6
2
.
4
 
(
2
4
–
9
0
)
6
1
7
 
c
o
m
p
a
r
a
t
o
r
s
:
 
 
2
 
e
x
p
l
o
r
a
t
o
r
y
 
b
i
m
a
t
o
p
r
o
s
t
 
f
o
r
m
u
l
a
t
i
o
n
s
1
8
7
–
3
7
4
1
2
r
,
 
D
M
,
 
A
C
,
 
P
G
M
e
a
n
 
I
O
P
6
3
.
5
 
(
2
3
–
9
4
)
N
o
t
e
:
 
s
t
u
d
y
 
3
a
 
w
a
s
 
a
 
t
h
r
e
e
-
y
e
a
r
 
e
x
t
e
n
s
i
o
n
 
o
f
 
s
t
u
d
i
e
s
 
1
 
a
n
d
 
2
;
 
a
t
 
b
a
s
e
l
i
n
e
,
 
a
l
l
 
p
a
t
i
e
n
t
s
 
h
a
d
 
r
e
c
e
i
v
e
d
 
1
2
 
m
o
n
t
h
s
 
o
f
 
t
r
e
a
t
m
e
n
t
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
C
,
 
a
c
t
i
v
e
-
c
o
n
t
r
o
l
l
e
d
;
 
B
I
D
,
 
t
w
i
c
e
 
d
a
i
l
y
;
 
D
M
,
 
d
o
u
b
l
e
-
m
a
s
k
e
d
;
 
I
O
P
,
 
i
n
t
r
a
o
c
u
l
a
r
 
p
r
e
s
s
u
r
e
;
 
P
G
,
 
p
a
r
a
l
l
e
l
 
g
r
o
u
p
;
 
Q
D
,
 
o
n
c
e
 
d
a
i
l
y
;
 
r
,
 
r
a
n
d
o
m
i
z
e
d
.Clinical Ophthalmology 2011:5
Table 2 Patient demographics in the pooled long-term glaucoma 
studies
Characteristic QD bimatoprost 
ophthalmic 
solution 0.03% 
(n = 926)
BID bimatoprost 
ophthalmic 
solution 0.03% 
(n = 483)
Age, years
  Mean ± standard deviation 61.5 ± 12.3 61.6 ± 12.0
  Median 63.0 63.0
  Minimum, maximum 22, 94 32, 91
Age distribution, %
  ,45 years 9.0 9.5
  45–65 years 50.0 47.6
  .65 years 41.0 42.9
Gender, %
  Male 46.2 48.4
  Female 53.8 51.6
race, %
  Caucasian 73.7 76.8
  Black 16.8 17.0
  Asian 1.4 2.7
  Hispanic 7.7 3.1
  Other 0.4 0.4
Abbreviations: BID, twice daily; QD, once daily.
Table 3 Common Aes ($5%) reported through month 12 in the 
six pooled long-term glaucoma studies
AE Incidence of AEs (%)
QD bimatoprost 
ophthalmic 
solution 0.03% 
(n = 926)
BID bimatoprost 
ophthalmic 
solution 0.03% 
(n = 483)
Conjunctival hyperemia 43.7 56.5
Growth of eyelashes 20.3 45.5
eye pruritus 10.7 16.1
skin hyperpigmentation 6.5 11.8
eye irritation 5.8 8.3
Dry eye 5.2 10.1
Hypertrichosis 5.1 9.1
Abbreviations: Aes, adverse events; BID, twice daily; QD, once daily.
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performed for AEs occurring during the first 12 months, 
24 months, 36 months, and 48 months.
AE terms from the individual studies were converted to 
Medical Dictionary for Regulatory Activities (MedDRA) 
Version 11.0. AEs were calculated based on the total number 
of patients who were randomized to each treatment group. 
If more than one episode of an AE was reported by any 
individual patient, it was counted only once for the period 
when it was first reported. Common AEs (incidence of $5% 
for QD bimatoprost ophthalmic solution 0.03% through 
the first 12 months) were tabulated; the incidence of each 
AE was tabulated regardless of causality or relationship 
to treatment. AE data were also tabulated by demographic 
subgroup.
Results
Demographics and treatment exposure
In the six pooled studies, 1409 patients received at least one 
dose of bimatoprost ophthalmic solution 0.03% QD or BID as 
an eyedrop. The aggregate numbers of patients receiving QD 
or BID bimatoprost ophthalmic solution 0.03% at months 4, 
6, 12, 24, 36, and 48 were 1258, 1238, 598, 153, 83, and 45, 
respectively. The median exposure to QD and BID bimato-
prost ophthalmic solution 0.03% was 365 days. As shown 
in Table 2, the mean age of the study population was 61.5 
years and 61.6 years for patients who received at least one 
dose of bimatoprost ophthalmic solution 0.03% QD or BID, 
respectively. In each bimatoprost treatment group, approxi-
mately 50% of patients were female and aged 45–65 years, 
and 73%–77% were Caucasian. The patients included 356 
non-Caucasians and represented approximately 25% of the 
study population, providing the ability to evaluate the safety 
of bimatoprost ophthalmic solution 0.03% across races.
Long-term Aes at 12 months
The six pooled studies showed that AEs, regardless 
of causality, were reported by 86.7% and 94.8% of 
patients receiving up to 12 months of treatment with 
either QD or BID bimatoprost ophthalmic solution 
0.03%, respectively. Most AEs were mild in severity. 
The most commonly reported AE through month 12 (inci-
dence of $5% among patients receiving   QD bimatoprost 
ophthalmic solution 0.03%) are summarized in Table 3. 
Common AEs included conjunctival hyperemia, growth 
of eyelashes, eye pruritus, skin hyperpigmentation, eye 
irritation, dry eye, and hypertrichosis. The incidence of 
these AEs was higher in the BID bimatoprost ophthalmic 
solution 0.03% group than in the QD group.
study/treatment discontinuations  
due to Aes
Among the 1409 patients treated with bimatoprost, 
220 subjects (110 for each treatment group)   discontinued 
study treatment before the end of the studies due to AEs. 
Most AEs leading to study or   treatment discontinuation 
(conjunctival hyperemia, growth of   eyelashes, eye pruri-
tus, skin hyperpigmentation, eye irritation, dry eye, and 
hypertrichosis) were ocular in nature, mild in severity, 
and occurred during the first 12 months (n = 97 and 99 
for patients receiving QD or BID bimatoprost ophthalmic 
solution 0.03%). Conjunctival hyperemia was the AE mostly Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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associated with early discontinuation from the studies, lead-
ing to discontinuation of 37 (4.0%, all occurring during the 
first 12 months) and 43 (8.7% during the first 12 months 
and 0.5% during more than 12–24 months) patients receiv-
ing QD or BID bimatoprost ophthalmic solution 0.03%, 
respectively.
sAes
Most SAEs reported in the pooled studies were nonocular, 
and were not considered by the investigators to be treatment-
related. Only one SAE in a timolol comparison study was 
considered by the investigator to be related to study treat-
ment, ie, chest pain. SAEs of the eye were reported by two 
patients in any bimatoprost treatment group (retinal vein 
occlusion and macular hole, but neither were considered 
by the investigator to be treatment-related). SAEs were 
reported by 103 (11.1%) and 51 (10.6%) patients in the QD 
and BID bimatoprost ophthalmic solution 0.03% groups 
through the 48 months, respectively (including events 
that were considered by the investigator to be unrelated to 
treatment).
Comparisons of sAes reported  
at months 4, 12, 24, 36, and 48
The cumulative incidence of common SAEs in the QD 
bimatoprost ophthalmic solution 0.03% group from three 
long-term, double-masked, and   open-label extension studies 
at 24, 36, and 48 months was similar to the AE profile after 
12 months of   treatment (Table 4).
Temporal onset of common Aes
The temporal onset of common AEs from the pooled stud-
ies was also evaluated. As illustrated in Figure 1, for most 
patients, the reported onset of common AEs was within four 
months of treatment initiation.
Aes by demographic group
The incidence of common AEs (Table 4) reported after 
12 months of treatment with QD bimatoprost   ophthalmic 
solution 0.03% was similar across age groups (,45, 45–65, 
and .65 years) although the rate of conjunctival hyper-
emia declined with age, from 50.6% (42/83) in patients 
aged ,45 years to 39.2% (149/380) in those aged .65 years 
(P = 0.016). In addition, the incidence of common AEs was 
similar across gender and race.
Discussion
This pooled analysis of safety data from six long-term studies 
showed that most AEs reported by patients receiving bimato-
prost ophthalmic solution 0.03% QD or BID as an eyedrop 
were ocular in nature, mild in   severity, and appeared early 
during treatment. The most common AEs, generally reported 
at an incidence of $5%, including conjunctival hyperemia, 
growth of   eyelashes, and eye pruritus, are consistent with 
AEs reported in other shorter-term studies.7,14 Moreover, as 
in other studies of bimatoprost ophthalmic solution 0.03%, 
these AEs rarely led to discontinuation from the study. Only 
4% of patients receiving QD bimatoprost ophthalmic solution 
0.03% discontinued the study or treatment due to conjunctival 
hyperemia, which was reported by 43.7% of patients. One 
limitation of this pooled analysis is that it does not include 
data for the eyelash hypotrichosis indication.
Common AEs were expected and consistent with the 
pharmacological mechanisms of bimatoprost.   Conjunctival 
hyperemia is a consequence of prostamide-induced vasodi-
lation, and is typically transient.2,18,19 In the recently com-
pleted phase III clinical study of bimatoprost ophthalmic 
solution 0.03% for treatment of hypotrichosis, the incidence 
of   conjunctival hyperemia was approximately an order of 
magnitude lower (3.6% with QD eyelid application versus 
Table 4 Cumulative incidence of common Aes reported at months 12, 24, 36, and 48 in the double-masked/open-label extension 
glaucoma studies with exposure 12–48 months
AE Cumulative incidence of AEs, %
QD bimatoprost ophthalmic 
solution 0.03% (n = 474)
BID bimatoprost ophthalmic 
solution 0.03% (n = 483)
#12 months #24 months #36 months #48 months #12 months #24 months
Conjunctival hyperemia 45.1 45.8 46.4 46.4 56.5 57.1
Growth of eyelashes 35.4 36.5 36.5 36.7 45.5 46.6
eye pruritus 13.9 14.3 14.6 14.8 16.1 16.4
skin hyperpigmentation 5.7 6.1 6.3 6.3 11.8 12.2
eye irritation 8.0 8.4 8.6 9.1 8.3 9.7
Dry eye 7.8 8.2 8.9 8.9 10.1 10.8
Hypertrichosis 8.2 8.6 8.9 8.9 9.1 9.1
Abbreviations: Ae, adverse event; BID, twice daily; QD, once daily.Clinical Ophthalmology 2011:5
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Figure  1  Temporal  onset  of  common  Aes  in  patients  receiving  bimatoprost 
ophthalmic solution 0.03% QD during the first 12 months of treatment in the six 
pooled long-term glaucoma studies.
Abbreviation: Ae, adverse event.
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43.7% with QD eyedrops) than in this pooled analysis.11 
This difference may be attributable to the 20-fold (for 
QD) and 40-fold (for BID) reduction in drug exposure 
when bimatoprost is applied to the upper eyelid margin in 
comparison with application as an eyedrop (Pers comm, 
Allergan, Inc). Furthermore, since the bimatoprost solu-
tion is applied to the skin for the hypotrichosis indication 
and not instilled directly into the eye, the skin barrier may 
further reduce eye and systemic exposure.
The frequency of iris color change, which appears to be an 
irreversible side effect associated with prostamides and pros-
taglandin analogs, was extremely low (0.9%) among patients 
receiving QD bimatoprost ophthalmic solution 0.03% in 
these glaucoma studies. This rate is consistent with reported 
rates of 1.1%–1.5% for bimatoprost and 5.1%–10.1% for 
latanoprost.18 Iris color change has not been reported in any 
clinical trials investigating patients receiving bimatoprost 
ophthalmic solution 0.03% for hypotrichosis.11
The incidence of skin hyperpigmentation among patients 
receiving QD bimatoprost ophthalmic solution 0.03% in the 
pooled analysis through 48 months was 6.3% from double-
masked, open-label-extension studies. This side effect is most 
often limited to the periocular area and appears to be revers-
ible following treatment discontinuation.18 The incidence 
of skin hyperpigmentation reported in a clinical study of 
bimatoprost ophthalmic solution 0.03% for eyelash growth 
was 2.9% and was not statistically more common than in the 
vehicle group.18
Conclusion
No unexpected safety signals were identified in this pooled 
analysis of studies involving continuous bimatoprost 
ophthalmic solution 0.03% use for ocular hypertension or 
glaucoma treatment for up to four years. All AEs reported 
(incidence $5%) were consistent with those previously 
encountered in clinical studies of bimatoprost. The most 
common AE, conjunctival hyperemia, is typically mild, 
transient, and rarely resulted in treatment   discontinuation. 
Only 4% of the patients treated QD discontinued due to 
conjunctival hyperemia, which occurred within the first year 
of treatment. Based on these six long-term studies in 1409 
patients with glaucoma, bimatoprost 0.03% has a favorable 
safety and tolerability profile when instilled in the eye. 
A long-term study to evaluate the effect of topical applica-
tion of bimatoprost to the eyelid margins on eyelash growth 
is currently underway.
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